News
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) Funding Update
HENDERSON, Nev., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) is continuing its ongoing negotiation with investors from Thailand, Japan, Switzerland, Luxembourg, USA, Bulgaria, and the UAE for financing of up to 50 million US dollars. The Company has seen great interest, with most investors reaching out directly to NIKA. “We are striving to select the most suitable investor and partner for NIKA, for which reason the discussions surrounding the technical details of
MagneINNO to Showcase Fully Chelated, Unbuffered Magnesium Glycinate at SupplySide West 2026
MagneINNO will showcase 8%, 10% and 12% elemental magnesium grades, proprietary seven-method chelation verification and California-stocked commercial supply at Booth #6145. Ontario, CA, Aug. 25, 2026 (GLOBE NEWSWIRE) -- MagneINNO, a B2B supplier focused on magnesium glycinate ingredients, will showcase its magnesium glycinate ingredient platform at SupplySide West 2026 in Las Vegas, where the company will exhibit at Booth #6145. The platform includes fully chelated, unbuffered magnesium glycinat
Standard Process Launches GI Soothing Supplement for Dogs and Cats
New probiotic, postbiotic, and botanical formula provides comprehensive gastrointestinal support during periods of digestive upset or distress A Media Snippet accompanying this announcement is available by clicking on this link. PALMYRA, Wis., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Standard Process® , a leader in whole food-based nutritional solutions, today announced GI Soothing , the newest addition to its Standard Process Veterinary line of human-quality supplements. Now available for preorder, GI
Genmab to Participate in Upcoming Investor Conferences
Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB ) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor conferences in September 2026 : Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, 2026, 3:00 PM EDT 24th Annual Morgan Stanley Global Healthcare Conference in New York City on September 15, 2026, 8:30 AM EDT Bank of America Global Healthcare Conference in London on September 22, 2
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8 + T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel
Olympia Pharmaceuticals Introduces Polidocanol 2% Injection for Targeted Cosmetic Vein Treatment
New injection gives healthcare providers a comfortable, effective option for cosmetic spider and reticular vein therapies ORLANDO, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals , a premier FDA-registered 503B outsourcing facility and 503A pharmacy, today announced the launch of its new Polidocanol 2% (20 mg/mL) injection . Expanding Olympia’s suite of specialized vein care offerings, this injection provides qualified healthcare professionals with a formulation that gently damag
Applied Biologics Announces Acceptance of Updated CAMPX XWRAP® Clinical Trial Results for Presentation at SAWC Fall 2026
Updated analysis of 222-patient randomized controlled trial demonstrates statistically significant improvement in complete diabetic foot ulcer closure with XWRAP plus standard of care SCOTTSDALE, Ariz., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel therapies for serious diseases with significant unmet medical needs, today announced that updated results from its CAMPX randomized controlled clinical trial evaluating XWRAP® in chronic diabetic foot
electroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
Recognition highlights Truvaga’s combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience ROCKAWAY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) , a bioelectronic technology company, today announced that Truvaga, its non-invasive vagus nerve stimulation (nVNS) wellness brand, has been named the 2026 Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards . The award recognize
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in September: Wells Fargo 2026 Healthcare Conference : Wednesday, September
Nu-Tek BioSciences to Attend BPI East 2026 in Boston, Connecting Animal-Free Culture Media Nutrients with Pharma Customer Growth Strategies
Tour Nu-Tek's state-of-the-art, 100% animal-free manufacturing facilty. Soy Peptone Soy peptones are one of the many animal-free products in Nu-Tek's raw materials portfolio. Nu-Tek will meet with pharmaceutical leadership during BioProcess International East Sept. 22-25 in Boston to discuss 100% animal-origin-free peptones and protein hydrolysates, with a focus on product quality and supply security. MINNETONKA, Minn., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nu-Tek BioSciences, the market leader in 1
Annovis to Host Corporate Update Webinar on September 2, 2026
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session. The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upc
Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium
Presentation addressed potential applications in prolonged field care and military wound management settings WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference rev
Ocugen to Participate in Upcoming September Investor and Industry Conferences
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026. Citi 2026 Biopharma Back to School Conference Location: JW Marriott Essex House, New York City, NY Date: Wednesday, September 9, 2026 Time: 3:40–4:15 p.m. ET Forma
Apollo Therapeutics Announces Positive Immunogenicity Data and Cross-Species Activity from Phase 1 Trial of APL-10456, a Pan-Rhinovirus Vaccine for the Prevention of COPD Exacerbations
Enrollment and dosing completed in Phase 1 randomized controlled trial (n=144) evaluating the safety, tolerability, immunogenicity and cross-species activity of APL-10456, an investigational rhinovirus vaccine Initial data show that a single dose of APL-10456 was well-tolerated, highly immunogenic, and induced Th1-polarized broad cross-rhinovirus species cellular immunity Additional data expected in Q4 2026, followed by initiation of a randomized, double-blind, placebo-controlled Phase 2 trial f
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on tr
BrewDog Wins Big at the 2026 World Beer Awards with a Sweeping Show of Brewing Excellence
Hazy Jane, Wingman and Mackie’s Two Scoops Earn Gold and Scotland Country Winner Awards, with Punk IPA, Lost Lager, Black Heart and Mello Also Recognised Among the World’s Best Beers ELLON, Scotland and LONDON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- BrewDog , a leader in U.K. craft beer and one of the world’s most recognised craft beer brands, by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), today announced a major moment for the brand at the 2026 World Beer Awards , the global awards selecting the
Immatics Announces $150 Million Underwritten Offering
Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 4,315,304 ordinary shares at a purchase price of $8.689 per pre-funded warrant,
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone payments GARDEN CITY, N.Y., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) today announced that they have entered into a definitive agreement under which UNIVO Pharmaceutical Industries Ltd (“UNIVO”) Univo Pharmaceutical Industries Ltd. ("UNIVO"), a public company whose shares ar
Revier Therapeutics Launches with €6 Million Seed Financing to Pioneer Class IIa HDAC Inhibitors for Cardiometabolic Disease
Heidelberg, Germany, August 25, 2026 – Revier Therapeutics (“Revier” or “the Company”), today announced the closing of a EUR 6 million seed financing and the launch of its operations. The Company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases. The financing was led by the KHAN Technology Transfer Fund II, with participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors t
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“ CDT ” or the “ Company ”), today announced that it has entered into a SAFE note with Pep'd Inc. (“ Pep'd ”), a US-based peptide company, expanding CDT's exposure to the growing US peptide market (the “ Transaction ”). Upon Pep’d closing an Equity Financing, this SAFE will automatically convert into a number of shares of Safe Preferred Stock, depending on the Pep’d Capitalization at that
3CLogic Releases AI Agent Evaluator to Automate QA and Scoring of Voice AI Agents
New capability scores 100% of AI interactions with plain-language reasoning, enabling accountability and rich insights into Voice AI engagements and performance. ROCKVILLE, Md. , Aug. 25, 2026 -- 3CLogic today announced the release of AI Agent Evaluator , a powerful automated quality assurance (QA) and scoring engine built natively into its Voice AI Hub . The new feature scores 100% of Voice AI agent interactions based on configurable metrics including resolution, goal completion, and quality, while providing plain-language reasoning behind each rating without the need for manual transcript review.
KSAT Delivers Integrated Mission Services for Kongsberg's N3X Satellite Constellation for Norway's Maritime Domain Awareness
SALT LAKE CITY , Aug. 25, 2026 -- Following KONGSBERG s announcement of an expansion of its N3X maritime surveillance constellation, Kongsberg Satellite Services (KSAT) highlighted its role as the operational backbone of the program, delivering Integrated Mission Services (IMS) for one of Norway s most strategically important space capabilities. The N3X satellites, developed and deployed by KONGSBERG, already provide maritime surveillance data to Norwegian authorities. KSAT is responsible for satellite operations, mission planning, global ground station access, data processing, and data delivery.
Transactions in connection with share buy-back program
Company announcement no. 32 - 26 25 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 3 - 26. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules. The purposes o
ZeroBounce Can Now Detect AI-Managed Mailboxes
New data helps businesses identify mailboxes managed by autonomous AI agents, going beyond traditional email validation. SANTA BARBARA, Calif. , Aug. 25, 2026 -- ZeroBounce, the email validation and deliverability platform, today announced it can now detect AI-managed mailboxes , a new layer of email intelligence that identifies mailboxes managed primarily by autonomous AI agents rather than people. ZeroBounce is the first email validation platform to provide customers with this type of insight.
Metabolon Completes Landmark Global Health Pilot Advancing Women's and Infant Health
Innovative sample collection methods developed through Gates Foundation-funded grant enable high-quality metabolomics biomarker discovery in populations from low- and middle-income countries MORRISVILLE, N.C. , Aug. 25, 2026 -- Metabolon, Inc., the global leader in metabolomics solutions advancing life science research, diagnostics, therapeutics, and precision medicine, today announced the successful completion of multiple pilot projects funded by the Gates Foundation (the foundation). These projects aimed to identify metabolites strongly associated with clinical outcomes for diseases and conditions that disproportionately affect women and infants in low- and middle-income countries.
Trading by management and close relations of management
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please see the full announcement in PDF.
Utility Global Taps Erik Meuleman as Chief Technology Officer to Advance Proprietary H2Gen Commercialization
Industry veteran brings 20+ years of experience advancing decarbonization technologies from research to commercial deployment HOUSTON , Aug. 25, 2026 -- Utility Global ( Utility ), a global company enabling economic industrial decarbonization, today announced the appointment of Erik Meuleman, Ph.D., as Chief Technology Officer. Meuleman joins Utility as the company continues rapid acceleration of its proprietary H2Gen technology from proven technology into broad commercial deployment, bringing more than two decades of experience advancing separation and carbon capture technologies from early-stage research through commercial-ready systems.
Participation notification by The Capital Group Companies, Inc.
Press release Communiqué de presse Participation notification by The Capital Group Companies, Inc. Brussels, Belgium – August 25, 2026 - 8:45 CEST According to Belgian transparency legislation (Law of May 2, 2007), The Capital Group Companies, Inc. (333 South Hope Street, 55th Fl, Los Angeles, CA 90071) recently sent Syensqo the following transparency notification indicating that it crossed the threshold of 5% for voting rights. Here is the summary of the move: Date on which the threshold was cr
Spinnaker Support Names Rex Young Chief Information Officer as Company Scales Global Operations
Veteran Tech Leader Brings 25-Plus Years of IT, Cybersecurity, and AI Experience to Modernize Platforms and Strengthen Security DENVER, Colo. , Aug. 25, 2026 -- Spinnaker Support , the third-party software support leader entrusted by 1,300+ global clients, today announced the appointment of Rex Young as Chief Information Officer (CIO). Reporting to CEO Matt Stava, Young will lead Spinnaker s global technology strategy as the company expands to meet the accelerating global demand for Oracle, SAP, VMware, and PostgreSQL support.
Relativity Accelerates Enterprise AI Transformation with Google Cloud's Gemini Enterprise for Legal
News Summary: RelativityOne now integrates with Google Cloud s Gemini Enterprise for Legal through the Model Context Protocol (MCP). This integration enables shared users to accelerate enterprise workflows with increased speed and security. The MCP integration for Gemini Enterprise is another informed step toward strengthening the intuitive experience of the company s AI platform for legal data intelligence, expanding the legal work it supports by bringing it to legal professionals where and how they work.
Industry Leaders Call for Cooling Security to Become a National Priority as India Accelerates Towards Viksit Bharat 2047
Grundfos-led roundtable at ISHRAE CoOL Conclave 3.0 identifies district cooling as a strategic enabler of energy security, sustainable urbanization, and net-zero growth COIMBATORE, India, Aug. 25, 2026 -- As India experiences unprecedented urban growth, rising temperatures, and increasing demand for cooling, industry leaders, policymakers, urban planners, utilities, developers, academics, and sustainability experts convened at ISHRAE CoOL Conclave 3.0 in Coimbatore to discuss one critical question: how can India secure its cooling future while continuing its path towards sustainable growth and Viksit Bharat 2047?
Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities
EAST RUTHERFORD, N.J. , Aug. 25, 2026 -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the successful completion of three Pre-Approval Inspections (PAIs) at its High Point, North Carolina facility by the U.S. Food and Drug Administration (FDA), Japan s Pharmaceuticals and Medical Devices Agency (PMDA), and Australia s Therapeutic Goods Administration (TGA). The completion of all three inspections enables High Point to manufacture approved active pharmaceutical ingredients (APIs) for the United States, Japan, and Australia, establishing the facility as the newest commercial manufacturing site within the Cambrex global network.
Zinnov Foundation Debuts New-Media Art Installation, Extends Dialogue to Community Hubs and Transit Infrastructure
BENGALURU, India, Aug. 25, 2026 -- Zinnov Foundation debuted a new-media art installation at Confluence 2026 that put visitors under real-time surveillance, using the experience to open a wider conversation about how technology is changing the way people encounter public spaces. Unveiled on Confluence s opening day, The Eye That Remembers is the work of artist Siddharth Kaneria, selected through an open call. The installation featured a grid of obsolete television sets displaying handcrafted cyanotype human eyes. Real-time tracking made the eyes follow visitors as they moved through the space, reversing the usual relationship between viewer and artwork.
Chandigarh University CSE Student Builds Tech-Driven Startup to Help Businesses Across IT, Digital Marketing and Networking Grow Fast in the Digital Era
University s Engineering Student s Startup Habonix Media Receives Rs. 3 Lakh Startup Seed Grant from Punjab Government CHANDIGARH, India, Aug. 25, 2026 -- Combining technology and creativity to help businesses grow efficiently in a competitive digital market, a Chandigarh University (CU) alumnus, Sabhay Khera, has founded a startup Habonix Media Pvt Ltd a one-stop solution provider for IT services, helping MSMEs and growing businesses build, scale, and succeed in the digital space offering end-to-end services including web and mobile app development, UI/UX (User Interface and User Experience) design and performance marketing solutions tailored to each client s goals.
YINZCAM AND HALO23 ANNOUNCE STRATEGIC PARTNERSHIP FOR GROWTH
Expanding unified digital platform across the GCC, Australia, and New Zealand. PITTSBURGH , Aug. 25, 2026 -- YinzCam and Halo23 today announced an exclusive strategic partnership to support YinzCam s growth across the GCC, Australia, and New Zealand. Halo23 brings deep business relationships across these markets, proven commercial expertise, and a track record of structuring complex partnerships for rights holders, venues, and operators. YinzCam brings the proven unified digital and data platform that these organizations need to compete and to undertake a comprehensive digital transformation.
Rising Demand for Advanced Gynecological Care: Rainbow Children's Hospital Expands Surgical Capabilities for Women
HYDERABAD, India , Aug. 25, 2026 -- Rainbow Children s Hospital recently introduced robotic-assisted surgery in its gynaecology department at its Financial District facility in Hyderabad, marking a step forward in the centre s approach to complex gynecological procedures. The technology allows surgeons to operate with greater precision and control, translating into smaller incisions, reduced blood loss, and faster recovery for patients undergoing procedures for conditions such as fibroids, endometriosis, and other gynecological disorders requiring surgical intervention.
Fractal establishes India Business Unit to meet increasing demand from large Indian enterprises
Will leverage its products portfolio led by Cogentiq MUMBAI, India, Aug. 25, 2026 -- Fractal Analytics Ltd . (BSE: 544700) (NSE: FRACTAL), a global enterprise AI company serving Fortune 500 organizations, today announced the launch of its dedicated India Business Unit (India BU), to help India s large enterprises accelerate business transformation through its enterprise agentic AI platform, Cogentiq , and other products.
STARTRADER Adds 30 U.S. Stock and ETF CFDs as 2026 Product Expansion Accelerates
PORT LOUIS, Mauritius , Aug. 25, 2026 -- STARTRADER evolves alongside global markets, expanding its product range to reflect client interests and trading habits. On 24 August , the company will add 30 new U.S. stock and ETF CFDs to MT5 , expanding its range of CFD exposure to companies and themes across technology, infrastructure and innovation. The expansion spans eight areas. Quantum computing additions include IONQ, QBTS, QUBT, ARQQ and QMCO ; software infrastructure includes ZS, S, RBRK and GTLB ; space and defence includes LUNR, PL, RCAT and BKSY ; while XE and NNE expand the range of CFDs linked to nuclear and energy themes.
Longeveron Announces 1-for-10 Reverse Stock Split
Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectivel
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026. Mr. Edwards brings more than 25 years of commercial leadership experience across im